Date: 2018-10-18
Type of information: Positive opinion for the granting of a Market Authorisation in the EU
Product name: Flucelvax® Tetra
Compound: influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated and prepared in cell cultures, of 4 different influenza virus strains (two A subtypes and two B types)
Therapeutic area: Infectious diseases
Action mechanism: vaccine
Company: Seqirus Netherlands, subsidiary of CSL (Australia)
Disease: prophylaxis of influenza in adults and children from 9 years of age
Latest news:
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE: 2018-10-18
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news: